[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-thyroidectomy-hypoparathyroidism-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-thyroidectomy-hypoparathyroidism-treatment":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100639834","calcium-replacement-therapy-in-postoperative-hypoparathyroidism-100639834",false,"NCT07577570","Calcium Replacement Therapy in Postoperative Hypoparathyroidism","A Pilot Study of Calcium Replacement Therapy in Postoperative Hypoparathyroidism","Inclusion Criteria:\n\n* patients over the age of 18 undergoing surgery involving both lobes of the thyroid gland (thyroidectomy, \"near-total\" thyroidectomy, subtotal thyroidectomy, and \"completed\" thyroidectomy)\n* Based on the first post-operative day analysis, PTH levels are below the normal range (in our hospitals 1.8-7.8 pmol\u002Fl), but not so low (below 1.06 pmol\u002FL) as to require calcium replacement therapy with calcitriol (rocaltrol)\n\nExclusion Criteria:\n\n* previously diagnosed osteoporosis; the patient is already taking calcium and vitamin D supplements prior to thyroid surgery\n* renal insufficiency (eGFR \\\u003C 30)\n* patients with concomitant hyperparathyroidism undergoing simultaneous thyroidectomy and parathyroidectomy for a parathyroid adenoma","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate whether a lower-dose calcium replacement therapy is non-inferior to a higher-dose regimen in preventing symptomatic hypoparathyroidism in patients following thyroidectomy. The hypothesis is:\n\n• lower-dose calcium replacement therapy is non-inferior to higher-dose therapy in preventing symptomatic hypoparathyroidism during the first two postoperative weeks\n\nResearchers will compare patients receiving a lower-dose calcium replacement regimen with those receiving a higher-dose regimen to assess whether the lower dose is not associated with a higher incidence of symptomatic hypoparathyroidism.\n\nPatients who develop post-thyroidectomy hypoparathyroidism are divided into groups for calcium replacement therapy. If they are asymptomatic, they will be scheduled for a follow-up visit at two weeks after surgery. During the follow-up visit, calcium metabolism will be evaluated, and treatment adjusted if necessary.",[26],"Post-Thyroidectomy Hypoparathyroidism Treatment",[28,29,30],"thyroidectomy","calcium replacement therapy","postoperative hypoparathyroidism","RECRUITING","2026-05-05",{"date":34,"type":35},"2026-05-11","ACTUAL",{"date":37,"type":35},"2025-11-18",{"date":39,"type":20},"2028-12",{"name":41,"class":42},"Tartu University Hospital","OTHER",2]